Skip to main content
TASLY PHARMACEUTICAL GROUP CO.,LTD. logo

TASLY PHARMACEUTICAL GROUP CO.,LTD. — Investor Relations & Filings

Ticker · 600535 ISIN · CNE000001C81 LEI · 300300JB9F71F58FIC88 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,889 across all filing types
Latest filing 2025-09-05 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600535

About TASLY PHARMACEUTICAL GROUP CO.,LTD.

http://www.tasly.com

Tasly Pharmaceutical Group Co., Ltd. specializes in the research, development, and production of modern Traditional Chinese Medicine (TCM), biological products, and chemical pharmaceuticals. The company is primarily known for its flagship cardiovascular treatment, Compound Danshen Dripping Pills, which represents a significant advancement in the modernization and standardization of herbal medicine. Its therapeutic portfolio covers cardiovascular, cerebrovascular, digestive, and metabolic diseases, as well as oncology. Tasly utilizes high-tech manufacturing processes and maintains a strong focus on R&D to bridge traditional therapies with modern clinical standards. The organization also explores digital health solutions and innovative drug delivery systems to enhance its comprehensive healthcare offerings.

Recent filings

Filing Released Lang Actions
天士力关于参加2025年天津辖区上市公司投资者网上集体接待日活动的公告
Regulatory Filings Classification · 95% confidence The document is an announcement about the company's participation in an online investor interaction event scheduled for September 11, 2025. It mentions that company executives will communicate with investors regarding the 2025 half-year performance, governance, strategy, and operations. The document is short (732 characters) and serves as a notice for an upcoming event rather than containing any financial data or detailed report. It does not contain actual financial statements or detailed analysis, nor is it a transcript or presentation. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a general regulatory announcement about investor relations activities and does not fit other specific categories.
2025-09-05 Chinese
天士力第九届董事会第13次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the 13th meeting of the 9th Board of Directors of TianShiLi Pharmaceutical Group Co., Ltd. It includes details about the meeting date, attendance, voting results, and references to other announcements but does not contain financial statements or detailed management discussion. The content focuses on board decisions and governance matters, such as approval of action plans and management system establishment. It is not a full annual or interim report, nor an earnings release or audit report. It is not a proxy solicitation or voting results announcement for shareholders but a board meeting resolution announcement. Therefore, the document fits best under Board/Management Information (MANG). The document length is short and specific to board resolutions, confirming this classification with high confidence.
2025-09-02 Chinese
天士力关于“提质增效重回报”行动方案的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement by the board of TianShiLi Pharmaceutical Group Co., Ltd. regarding their "Quality Improvement, Efficiency Enhancement, and Return to Shareholders" action plan. It discusses the company's strategic initiatives, operational performance for the first half of 2025, governance improvements, innovation and R&D focus, investor relations, and dividend distribution plans. The document is a detailed corporate announcement outlining future plans and current achievements rather than a formal financial report or regulatory filing. It does not contain full financial statements or detailed quarterly/annual financial data, nor is it a transcript, proxy, or legal proceeding. It is not a short notice about a report publication but a substantive announcement of a corporate action plan. Therefore, it fits best under the category of a Capital/Financing Update (CAP) as it relates to company strategy, operational quality improvement, and shareholder returns, including dividend plans and financial performance highlights.
2025-09-02 Chinese
天士力2025年第四次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is titled as a resolution announcement for the 2025 fourth extraordinary shareholders' meeting of the company. It details the meeting date, attendance, voting results on a profit distribution proposal, and legal witness statements. It does not contain full financial statements or detailed financial analysis but rather the official voting results and meeting procedural information. This matches the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short and focused on voting outcomes, not a full report or presentation. Therefore, the correct classification is DVA with high confidence.
2025-09-02 Chinese
内蒙古建中律师事务所关于天士力医药集团股份有限公司2025年第四次临时股东大会的法律意见书
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the procedures, attendance, and voting results of the 2025 fourth extraordinary general meeting of shareholders of a company. It details the convening, attendance, voting procedures, and results of the shareholders' meeting. It is not the meeting materials themselves, nor a report of financial results, nor a regulatory filing or announcement. It is a legal opinion related to a shareholders meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (2158 characters), but it contains substantive content about the voting results and legal validation, not just an announcement of a report publication. Therefore, the best fit is DVA.
2025-09-02 Chinese
天士力2025年第四次临时股东大会会议资料
AGM Information Classification · 95% confidence The document is titled as "2025 年第四次临时股东大会会议资料" which translates to "2025 Fourth Extraordinary General Meeting (EGM) Meeting Materials." It contains detailed agenda items, voting methods, attendance information, and a profit distribution proposal to be voted on by shareholders. The content is typical of materials prepared for a shareholders' meeting, including legal opinions and voting procedures. It is not a report of voting results, nor is it a proxy solicitation or a report publication announcement. It is clearly the meeting materials presented to shareholders for the EGM. Therefore, this document fits the category of AGM Information (AGM-R), which includes presentations and materials shared during general meetings (including extraordinary meetings). The document length is under 5,000 characters, but it contains substantive meeting materials, not just an announcement of a report. Hence, the classification is AGM-R with high confidence.
2025-08-22 Chinese

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.